Veru Inc. CEO to Speak at Biomed Israel 2024 Conference
MIAMI, FL, May 14, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a leading biopharmaceutical company specializing in innovative medicines for weight loss, oncology, and respiratory distress syndrome, has announced that Mitchell Steiner, M.D., Chairman, President, and CEO, will be a Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week in Tel Aviv, Israel.
The keynote presentation will address concerns related to muscle loss caused by certain weight loss medications, the rebound effect upon stopping these medications, and the impact on older patients at risk for frailty. The presentation is scheduled for May 22, 2024, and will focus on making weight loss drugs more effective by preserving muscle mass.
The Phase 2b clinical trial for enobosarm, a novel treatment to preserve muscle and augment fat loss in elderly patients, is actively enrolling participants in the United States. The trial aims to evaluate the safety and efficacy of enobosarm in patients with sarcopenic obesity or overweight elderly individuals.
Veru Inc. is dedicated to developing innovative treatments for metabolic diseases, oncology, and respiratory distress syndrome. Their drug development program includes enobosarm and sabizabulin, with a focus on addressing unmet medical needs in these areas.
For more information on Veru Inc. and their upcoming developments, visit their website or contact Samuel Fisch, Executive Director of Investor Relations and Corporate Communications.
Contact:
Samuel Fisch
Executive Director, Investor Relations and Corporate Communications
Email: veruinvestor@verupharma.com
Stay tuned for updates on the Phase 2b clinical trial and the future of innovative treatments from Veru Inc. at Biomed Israel 2024.